AzTrials
AzTrials

Heart TransplantationNCT05243914

Heart Transplantation Utilizing NRP DCD

An observational study of Heart Transplantation and Perfusion, run by University of Arizona at 1 site in United States.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

This is a prospective, observational, pilot trial to evaluate the feasibility of heart transplantation using normothermic regional perfusion (NRP) donation after donor circulatory death (DCD). Read more about this study

Who is it for?
Ages 18 to 65 years
How many people
56 participants
Where
1 siteUnited States
Study dates
21 Jan 2022to 3 Jan 2024
How long will I take part?
1 Year
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: We anticipate evaluating an initial cohort of approximately 100 DCD donors for a final yield of 40 hearts suitable for transplantation. Donors will be between the ages of 18 and 65 who are determined to have heart function/quality that is appropriate for donation for transplantation based on available donor data and testing. Donors might be transported to BUMCP with the intent of implanting the recipients at BUMCP. It is preferable to relocate the donor and recipient to maintain uniformity of process, minimize cold ischemic time and allow for rapid and improved communication during the initial pilot phase.

Who may be able to join

  • Recipient Inclusion Criteria
  • Recipient is ≥ 18 years old
  • Recipient, or their designated healthcare proxy, is able and willing to sign an informed consent
  • The recipient meets standard listing criteria for heart transplantation.

Who cannot join

  • Recipient is < 18 years old
  • Recipient, or their designated healthcare proxy, is unable to sign an informed consent
  • The recipient is participating in another interventional trial
  • The recipient has a known history of HIV infection
  • The recipient has any condition that, in the opinion of the Investigator, would make study participation unsafe or would interfere with the objectives of the study

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Banner University Medical Center Phoenix

    Phoenix, Arizona, 85006

Other trials in United States

About this study

Official title: Heart Transplantation Using Normothermic Regional Perfusion (NRP) Donation After Circulatory Death (DCD): A Pilot Study

This is a prospective, observational, pilot trial to evaluate the feasibility of heart transplantation using normothermic regional perfusion (NRP) donation after donor circulatory death (DCD). Adults who meet standard criteria for heart transplantation listing and study-specific eligibility criteria will enroll in the study.

the investigators anticipate evaluating an initial cohort of approximately 100 DCD donors for a final yield of 40 hearts. The investigators will accept donors between the ages of 18 and 65 who are determined to have heart function/quality appropriate for donation for transplantation based on available donor data and testing.

Read more

If feasible, donors might be relocated to BUMCP to maintain uniformity of process, minimize cold ischemic time, and allow for more rapid and improved communication during the initial pilot phase.

Recipients will be selected based on blood group, crossmatch, size match, and clinical stability per standard allocation practices. Recipients will be followed post-transplantation per BUMCP Heart Transplant standard protocol.

Read the detailed description

The surgical management of end-stage heart failure generally falls into two categories: mechanical circulatory support and heart transplantation. The availability of suitable organs intrinsically limits the rate of heart transplantation. The vast majority of cadaveric donor hearts are obtained from patients who have had irreversible cessation of neurological function (DBD - Donation after Brain Death). Recently, there has been renewed interest in the possibility of obtaining cadaveric hearts from DCD (Donation after Circulatory Death) donors who have had irreversible cessation of cardiopulmonary function. In contrast to DBD, DCD involves the intentional withdrawal of life support measures to allow controlled circulatory death to occur. If the patient fails to progress to circulatory death within the allotted time, DCD donation is terminated, and the patient is placed on comfort measures until they expire.

The concept of DCD heart transplantation is not new. Barnard used DCD hearts in his early series of heart transplants because the idea of brain death had not yet been well established. Clinical DCD heart transplant programs have been established in the UK, Belgium, and Australia. However, DCD heart transplantation currently remains virtually nonexistent in the US. DCD can increase the available US heart donor pool by as much as 20%. Of the more than 41,000 adult heart transplants performed in the US over the past 20 years, only 4 have been from DCD donors. Perhaps understandably, there is some hesitance in using a donor heart that has just undergone circulatory death.

Potential DCD donors are stratified according to the Maastricht classification system: 1) dead on arrival at the hospital, 2) out-of-hospital arrest with unsuccessful resuscitation, 3) circulatory arrest as a result of a planned withdrawal of life support, 4) circulatory arrest in a patient who is already brain-dead, and 5) circulatory arrest while in the hospital with unsuccessful resuscitation. Categories 1, 2, and 5 would be considered "uncontrolled" DCD. Categories 3 and 4 are considered "controlled" DCD, where the duration and conditions of warm ischemia are known, and the precise course of circulatory arrest can be followed.

The current procedure of DCD organ donation and procurement follows a well-established course for lung, liver, kidney, and pancreas transplantation in the United States. After consent has been obtained, the organs are allocated through the United Network of Organ Sharing (UNOS). When all parties are present and ready, the donor is withdrawn from life support (i.e., discontinuation of mechanical ventilation and any vasoactive medications). The surgical teams are generally present on the premises but not at the donor's bedside. After circulatory arrest occurs, which is determined by the absence of pulse and organized rhythmic cardiac activity, death is declared by a physician not associated with the transplant teams. Subsequently, a standoff period is observed (5 minutes) to ensure a complete cessation of the circulation before organ procurement is commenced. If after withdrawal of life support, the patient does not progress to circulatory death within the allotted time (variable among hospitals, but 60 minutes in this study), the procurement is abandoned, and the patient is transferred out of the operating room and placed on palliative measures.

Given that DCD organ donation is already currently practiced in the US, the same standard approach defined by each state and locality can also be applied to DCD heart donation. However, this protocol will utilize a normothermic regional perfusion (NRP) strategy that involves the re-establishment of circulatory blood flow after the period of circulatory arrest has been established and the 5 minutes of standoff time has passed. The local Organ Procurement Organization (Donor Network of Arizona-DNAZ) and BUMCP Leadership have reviewed and approved this approach to DCD heart donation. Specifically, normothermic regional perfusion involves the following steps:

  1. Opening the chest through a standard sternotomy used for heart and lung procurement.
  2. Ligation of all the blood vessels that supply blood to the brain to ensure that blood flow to the brain is not re-established once circulation is restarted, as described below.
  3. Standard cannulation of the aorta and the right atrium as is done for cardiac surgical procedures.
  4. Initiation of cardiopulmonary bypass, which will re-establish blood flow to all organs of the body, including the heart under normothermia. The initial step for ligation of the blood vessels to the head is necessary to ensure that blood flow to the brain does not occur.

Once blood flow to the heart is established, the heart will start beating. At 30 to 60-minute intervals, the donor will be separated from cardiopulmonary bypass, and the heart will be assessed for functionality. If accepted, standard DBD procurement will commence. The heart transplantation surgery on the potential recipient will only begin once the heart has been accepted as suitable.

If, after assessment, the heart is not suitable, cardiopulmonary bypass will be restarted. The donor heart will be reassessed at 30-minute intervals up to 180 minutes. If no significant acceptable recovery occurs and the heart is not deemed suitable for transplantation, then the study will be terminated, but the remaining organs can be recovered as standard practice.

Although there has been limited experience with DCD heart donation in the US up to this point, they are being performed with increasing frequency in Europe and Australia. Although protocols already exist for DCD donation for other organs, there is currently no established US consensus for DCD hearts.

To date researchers have found comparable short-term and midterm results between the standard and DCD heart transplantation techniques, however the longer-term results are unknown at this time. This study will help us learn more about the long-term outcomes and see how well the DCD technique works for heart transplant.

Although the investigators report comparable short-term and midterm results between DBD and DCD heart transplantation, the longer-term results are unknown Regardless of the retrieval protocol utilized, there is now sufficient accumulated clinical experience to indicate that heart transplants from selected DCD donors are associated with outcomes comparable to those observed with DBD donors.

Keywords
Normothermic Regional Perfusion (NRP), Donation After Circulatory Death (DCD), Heart Transplantation, Observational Study

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Evaluation of feasibility

    To evaluate the survival of heart transplantation recipients using normothermic regional perfusion (NRP) donation after circulatory death (DCD).

    Measured: through study completion, an average of 1 year

Secondary outcomes (1)
  1. Evaluation of Incidence of Rejection

    To evaluate incidence of rejection over an extended period of pump-assisted reperfusion for DCD heart donation.

    Measured: through study completion, an average of 1 year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 Feb 2022
  2. Study start21 Jan 2022
  3. Primary completion4 Jul 2023
  4. Study completion3 Jan 2024

Why it stopped: Slow study enrollment

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
56 participants (actual)
Target duration
1 Year
IDs, dates and publications
ClinicalTrials.gov ID
NCT05243914
Sponsor's protocol ID
STUDY00000230
Status last verified
Mar 2024
First submitted
21 Jan 2022
Last updated
13 Mar 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: Data collected for this study will be analyzed and stored in a HIPAA compliant REDCap database hosted by UA. After the study is complete, the de-identified, archived data will be retained in REDCap per the UA IRB guidelines. When the study is complete, access to study data will be provided through REDCap. This study will adhere to the UA policy for data sharing.

Questions about this trial

What is this clinical trial studying?

An observational study of Heart Transplantation and Perfusion, run by University of Arizona at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 13 Mar 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study was stopped early (reason given: Slow study enrollment). Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Evaluation of feasibility (time frame: through study completion, an average of 1 year). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Mar 2024.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in